KFDA approves additional indication of Ultracet

Published: 2004-01-19 06:56:00

Updated: 2004-01-19 06:56:00

The Korea Food and Drug Administration said that it approved another indication of Janssen Korea's Ultracet for the relief of moderate to severe pain in addition to the short-term management of acute pain.

Thus Ultracet can be applied to patients with chronic pain for the relief of many kinds ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK